Synlogic is an early-stage developer of “synthetic biotic” medicines — therapeutics consisting of beneficial microbes genetically engineered to treat rare metabolic diseases.
An exclusive interview with Rachel King, a business person dedicated to a science-driven sector, who is CEO of GlycoMimetics, an oncology-focused biotechnology company.
This 15-person virtual biotech is trying to stop immune-mediated disease early, before it becomes a chronic condition.
Medicines360 is using all its developed-world revenue to extend access to essential medicines to all women, regardless of the economic and healthcare circumstances in their part of the world.
Garo Armen, CEO of Agenus and a long-time pharma industry veteran, has shown the instincts for simple money-making on one hand and the humanitarian side of biopharma on the other.
Vyome Therapeutics has built platforms and is developing products that address antibiotic resistance in severe skin conditions.
An in-depth look at the career and accomplishments of Howard Fillit, M.D., who has long led the exploration of Alzheimer’s disease outside and inside of the biopharma industry.
Azitra is a small, young, early-stage company developing microbial biotherapeutics for conditions arising on the skin that can be addressed by using the microbiome.
At the end of every year since we began the monthly column, Companies to Watch, I have gone back to the featured companies and asked each one to send me a short assessment of its progress since it appeared in Life Science Leader.
An in-depth look at three developers that exemplify the range of new approaches and alternatives in the IO combo space: Oncosec Medical, Heat Biologics, and Rexahn.
Synspira is developing glycopolymer drugs for infection, inflammation, and congestion in the lungs. According CEO Shenda Baker, “We would like to see more companies in this space. But we are also looking forward to leading the way.”
Biopharma executives in companies of all sizes share their views on whether the now dominant life sciences industry business model, with its focus on rare diseases affecting small patient populations, allows companies to meet their historical public-health obligation.
The ARM Foundation for Cell and Gene was launched in June, and it marks a new stage in development of the RM space as it moves from an early era or “promise” to one of fulfillment. Today, nearly 900 companies worldwide are developing RM therapies.
Athersys is mass-producing off-the-shelf stem cells for multiple conditions in the cardiovascular, neurological, inflammatory, and immune disease areas.
